Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: results from a prespecified subgroup analysis of the CASSINI study
dc.contributor.author | Vadhan-Raj, S | |
dc.contributor.author | McNamara, Mairead G | |
dc.contributor.author | Venerito, M | |
dc.contributor.author | Riess, H | |
dc.contributor.author | O'Reilly, EM | |
dc.contributor.author | Overman, MJ | |
dc.contributor.author | Zhou, X | |
dc.contributor.author | Vijapurkar, U | |
dc.contributor.author | Kaul, S | |
dc.contributor.author | Wildgoose, P | |
dc.contributor.author | Khorana, AA | |
dc.date.accessioned | 2019-11-19T16:01:08Z | |
dc.date.available | 2019-11-19T16:01:08Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Vadhan-Raj S, McNamara MG, Venerito M, Riess H, O'Reilly EM, Overman MJ, et al. Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: results from a prespecified subgroup analysis of the CASSINI study. J Clin Oncol. 2019;37(15_suppl):4016-. | en |
dc.identifier.doi | 10.1200/JCO.2019.37.15_suppl.4016 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622471 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.4016 | en |
dc.title | Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: results from a prespecified subgroup analysis of the CASSINI study | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | The University of Texas MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Section of Cytokines and Supportive Oncology, Houston, TX | en |
dc.identifier.journal | Journal of Clinical Oncology | en |